SU-E-T-466: Dosimetric Assessment of the Salivary Glands in Head and Neck Tumour Patients Treated with Radiation Therapy

2014 ◽  
Vol 41 (6Part18) ◽  
pp. 333-333
Author(s):  
Xavier C Peixoto ◽  
Ferreira B Costa ◽  
L Khouri ◽  
M Lopes ◽  
S Stathakis ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck ◽  
Salivary Glands ◽  
Neck Tumour ◽  
Dosimetric Assessment

scholarly journals Reducing Xerostomia by Comprehensive Protection of Salivary Glands in Intensity-Modulated Radiation Therapy with Helical Tomotherapy Technique for Head-and-Neck Cancer Patients: A Prospective Observational Study

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Feng Teng ◽  
Wenjun Fan ◽  
Yanrong Luo ◽  
Zhongjian Ju ◽  
Hanshun Gong ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Salivary Glands ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Helical Tomotherapy ◽  
Clinical Stage ◽  
Flow Rates ◽  
Saliva Flow

Objective. This study aimed to analyze the effects of comprehensive protection of bilateral parotid glands (PG-T), contralateral submandibular gland (cSMG), and accessory salivary glands in the oral cavity (OC) by helical tomotherapy for head-and-neck cancer patients. Methods. Totally 175 patients with histologically confirmed head-and-neck cancer treated with helical tomotherapy were recruited. The doses delivered to PG-T, cSMG, and OC were constrained to be as low as possible in treatment planning. The saliva flow rates and xerostomia questionnaire were evaluated. Correlation between xerostomia and other clinical factors were assessed using univariate and multivariate models. The impact of salivary gland dose on locoregional (LR) recurrence was assessed by Cox analysis. ROC curve was used to determine the threshold of mean dose for each gland. Results. The median follow-up was 25 (19–36) months. The OC mean dose, PG-T mean dose, cSMG mean dose, age, clinical stage (II and III versus IV), and both unstimulated and stimulated saliva flow rates were significantly correlated with xerostomia. The OC mean dose, cSMG mean dose, age, and clinical stage were predictors of xerostomia after adjusting PG-T mean dose, and unstimulated and stimulated saliva flow rates. Xerostomia was significantly decreased when the mean doses of PG-T, cSMG, and OC were kept below 29.12Gy, 29.29Gy, and 31.44Gy, respectively. At 18 months after radiation therapy, early LR recurrence rate was only 4%. Conclusion. Comprehensive protection of salivary glands minimized xerostomia in head-and-neck cancer patients treated by helical tomotherapy, without increasing early LR recurrence risk.

SU-D-204-04: Correlations Between Dosimetric Indices and Follow-Up Data for Salivary Glands Six Months After Radiation Therapy for Head and Neck Cancer

2016 ◽  
Vol 43 (6Part3) ◽  
pp. 3332-3333
Author(s):  
B Chera ◽  
A Price ◽  
M Kostich ◽  
R Amdur ◽  
W Mendenhall ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Salivary Glands ◽  
Neck Cancer ◽  
Dosimetric Indices

scholarly journals Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes

2018 ◽  
Vol 115 (24) ◽  
pp. 6279-6284 ◽  
Author(s):  
Julie P. Saiki ◽  
Hongbin Cao ◽  
Lauren D. Van Wassenhove ◽  
Vignesh Viswanathan ◽  
Joshua Bloomstein ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Salivary Glands ◽  
Aldehyde Dehydrogenase ◽  
Neck Cancer ◽  
Common Side Effect ◽  
Loss Of Function ◽  
And Function

Xerostomia (dry mouth) is the most common side effect of radiation therapy in patients with head and neck cancer and causes difficulty speaking and swallowing. Since aldehyde dehydrogenase 3A1 (ALDH3A1) is highly expressed in mouse salivary stem/progenitor cells (SSPCs), we sought to determine the role of ALDH3A1 in SSPCs using genetic loss-of-function and pharmacologic gain-of-function studies. Using DarkZone dye to measure intracellular aldehydes, we observed higher aldehyde accumulation in irradiated Aldh3a1−/− adult murine salisphere cells and in situ in whole murine embryonic salivary glands enriched in SSPCs compared with wild-type glands. To identify a safe ALDH3A1 activator for potential clinical testing, we screened a traditional Chinese medicine library and isolated d-limonene, commonly used as a food-flavoring agent, as a single constituent activator. ALDH3A1 activation by d-limonene significantly reduced aldehyde accumulation in SSPCs and whole embryonic glands, increased sphere-forming ability, decreased apoptosis, and improved submandibular gland structure and function in vivo after radiation. A phase 0 study in patients with salivary gland tumors showed effective delivery of d-limonene into human salivary glands following daily oral dosing. Given its safety and bioavailability, d-limonene may be a good clinical candidate for mitigating xerostomia in patients with head and neck cancer receiving radiation therapy.

Radiation-Associated Carcinoma of the Salivary Glands a Controlled Study

1981 ◽  
Vol 90 (2) ◽  
pp. 107-108 ◽  
Author(s):  
Harry R. Maxon ◽  
Eugene L. Saenger ◽  
Stephen R. Thomas ◽  
Margaret L. Shafer ◽  
C. Ralph Buncher ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Salivary Gland ◽  
Head And Neck ◽  
Salivary Glands ◽  
Radiation Field ◽  
Controlled Study ◽  
External Radiation ◽  
Significant Excess ◽  
Benign Diseases ◽  
External Radiation Therapy

Five hundred fifty-four persons were evaluated who had received external radiation therapy for benign diseases of the head and neck in childhood and whose salivary glands were presumably included in the radiation field. A significant excess of salivary gland cancers were noted when they were compared to 958 nonirradiated control subjects.

Sign in / Sign up

Export Citation Format

Share Document